Takeda Pharmaceutical Company (4502) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
29 Oct, 2026Executive summary
H1 FY2026 revenue was JPY 2,407.0B, up 8.4% reported but down 1.0% CER; core operating profit rose 11.2% reported and 0.7% CER to JPY 710.6B.
Transformation savings helped fund launches and R&D; FY2026 core operating profit guidance increased to JPY 1,190B, mainly on FX benefits.
Financial highlights
H1 reported operating profit rose 60.4% to JPY 406.7B; net profit attributable to owners was JPY 305.6B, up 171.8% reported.
H1 core net profit was JPY 489.6B, up 11.6% reported and down 0.2% CER; core EPS was JPY 308, up 10.5% reported and down 1.2% CER.
Q2 revenue was JPY 1,187.1B, down 1.6% CER; core operating profit was JPY 351.7B, up 1.9% CER.
H1 operating cash flow was JPY 431.9B, down 27.2%; adjusted free cash flow was JPY 325.7B, down 38.0%.
Outlook and guidance
FY2026 revenue guidance rose JPY 60B to JPY 4,700B; the low-single-digit CER decline outlook was maintained.
Core operating profit guidance increased JPY 30B to JPY 1,190B and core EPS to JPY 482, mainly reflecting transactional FX benefits.
Reported operating profit guidance rose to JPY 453B, net profit to JPY 209B and basic EPS to JPY 131; adjusted FCF guidance increased to JPY 700B–800B.
CER guidance indicates mid-single-digit core operating profit decline and low-teens core EPS decline; stronger LOE-affected and mature-portfolio revenue is partly offset by Albumin and QDENGA weakness.
FY2026 restructuring costs are forecast at JPY 160B; CAPEX guidance is JPY 330B–380B and annual dividend guidance remains JPY 204 per share.
Latest events from Takeda Pharmaceutical Company
- Strategic shift and robust pipeline drive upcoming launches and data milestones.4502
Morgan Stanley 24th Annual Global Healthcare Conference - Q1 revenue up 10.2% on FX; core profit flat at CER; new launches offset mature declines.4502
Q1 2027 - Three major launches and a transformation plan set the stage for renewed growth and efficiency.4502
Jefferies Global Healthcare Conference 2026 - Zasocitinib achieved rapid, durable skin clearance and strong safety in phase III psoriasis trials.4502
Study Update - Oveporexton phase III trials in NT1 achieved robust efficacy and safety across all symptom domains.4502
Study Update - Net profit rose 30.4% despite revenue decline, with pipeline and cash flow strength supporting guidance.4502
Q1 2026 - H1 revenue and profit surged, guidance raised, but H2 faces Vyvanse erosion and higher R&D costs.4502
Q2 2025 - Q1 revenue up 2.1% at CER, but net profit faces pressure from costs and Vyvanse erosion.4502
Q1 2025 - Growth and launch products drove revenue and margin gains, with flat core outlook and higher dividend.4502
Q4 2025